Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

The drug's ability to target CDK4/6 directly, leading to cell cycle arrest and reduced tumor growth, positions it as a candidate for further investigation in the chemoprevention and treatment of ESCC.

Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial cell cycle regulators and have become significant targets in breast cancer therapy. Current CDK4/6 inhibitors, while effective, often come with ...

Although the novel CDK4 + CDK6 inhibitor was given orally, its rapid clearance in vivo necessitated the use of fairly high doses. The authors note that cell-cycle inhibitors suppress arthritis via ...

Work in our group over the last four years studying the effect of CDK4/6 inhibition in cancer cells has uncovered a new relationship between quiescence and senescence, a more permanent form of cell ...